2-MPPA GPI-5693,98.0%
产品编号:Bellancom-103345| CAS NO:254737-29-6| 分子式:C8H14O4S| 分子量:206.26
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用,
2-MPPA GPI-5693
产品介绍 | 2-MPPA (GPI-5693) 是一种具有口服活性的、选择性的谷氨酸羧肽酶 II (GCP II; PSMA) 抑制剂,IC50 值为 90 nM。 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
生物活性 | 2-MPPA (GPI-5693) is an orally active and selective glutamate carboxypeptidase II (GCP II; PSMA) inhibitor with an IC50 of 90 nM. | ||||||||||||||||
体外研究 | |||||||||||||||||
体内研究 |
2-MPPA (10, 30 or 100 mg/kg) significantly attenuates Dizocilpine (HY-15084B) (0.1 mg/kg)-induced prepulse inhibition (PPI) deficits in mice, in a dose dependent manner. The efficacy of 2-MPPA on dizocilpine-induced PPI deficits is significantly antagonized by pretreatment with the selective group II metabotropic glutamate receptor (mGluR) antagonist LY341495 (HY-70059) (1.0 mg/kg). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
体内研究 |
2-MPPA (10, 30 or 100 mg/kg) significantly attenuates Dizocilpine (HY-15084B) (0.1 mg/kg)-induced prepulse inhibition (PPI) deficits in mice, in a dose dependent manner. The efficacy of 2-MPPA on dizocilpine-induced PPI deficits is significantly antagonized by pretreatment with the selective group II metabotropic glutamate receptor (mGluR) antagonist LY341495 (HY-70059) (1.0 mg/kg). 西域 has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
性状 | Oil | ||||||||||||||||
溶解性数据 |
In Vitro:
DMSO : 100 mg/mL (484.82 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo:
请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
参考文献 |